Publication

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., Whenham, N., Sanghera, P., Weller, M., Dubbink, H. J., French, P., Looman, J., Dey, J., Krause, S., Ansell, P., Nuyens, S., Spruyt, M., Brilhante, J., Coens, C., Gorlia, T. & Golfinopoulos, V., 15-May-2020, In : Neuro-Oncology. 22, 5, p. 684-693 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Martin Van Den Bent
  • Marica Eoli
  • Juan Manuel Sepulveda
  • Marion Smits
  • Annemiek Walenkamp
  • Jean-Sebastian Frenel
  • Enrico Franceschi
  • Paul M Clement
  • Olivier Chinot
  • Filip De Vos
  • Nicolas Whenham
  • Paul Sanghera
  • Michael Weller
  • H J Dubbink
  • Pim French
  • Jim Looman
  • Jyotirmoy Dey
  • Scott Krause
  • Pete Ansell
  • Sarah Nuyens
  • Maarten Spruyt
  • Joana Brilhante
  • Corneel Coens
  • Thierry Gorlia
  • Vassilis Golfinopoulos

BACKGROUND: Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody-drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma.

METHODS: Eligible were patients with centrally confirmed EGFR amplified glioblastoma at first recurrence after chemo-irradiation with temozolomide. Patients were randomized to either Depatux-M 1.25 mg/kg every 2 weeks intravenously, or this treatment combined with temozolomide 150-200 mg/m2 day 1-5 every 4 weeks, or either lomustine or temozolomide. The primary endpoint of the study was overall survival.

RESULTS: Two hundred sixty patients were randomized. In the primary efficacy analysis with 199 events (median follow-up 15.0 mo), the hazard ratio (HR) for the combination arm compared with the control arm was 0.71 (95% CI = 0.50, 1.02; P = 0.062). The efficacy of Depatux-M monotherapy was comparable to that of the control arm (HR = 1.04, 95% CI = 0.73, 1.48; P = 0.83). The most frequent toxicity in Depatux-M treated patients was a reversible corneal epitheliopathy, occurring as grades 3-4 adverse events in 25-30% of patients. In the long-term follow-up analysis with median follow-up of 28.7 months, the HR for the comparison of the combination arm versus the control arm was 0.66 (95% CI = 0.48, 0.93).

CONCLUSION: This trial suggests a possible role for the use of Depatux-M in combination with temozolomide in EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line adjuvant temozolomide treatment. (NCT02343406).

Original languageEnglish
Pages (from-to)684-693
Number of pages10
JournalNeuro-Oncology
Volume22
Issue number5
Publication statusPublished - 15-May-2020

Download statistics

No data available

ID: 134525246